Triple-S Management Corporation
Triple-S Management Corporation (GTS) Stock Competitors & Peer Comparison
See (GTS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GTS | $35.99 | +1.04% | 0 | 10.41 | $3.46 | N/A |
| UNH | $307.42 | +1.34% | 278.4B | 13.32 | $23.08 | +2.78% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | N/A |
| CVS | $71.30 | -0.18% | 90.4B | 19.86 | $3.59 | +3.74% |
| CI | $304.35 | +1.13% | 81.2B | 16.68 | $18.24 | +1.91% |
| ELV | $316.55 | +2.24% | 71.2B | 13.42 | $23.56 | +2.11% |
| HUM | $299.51 | +1.71% | 36B | 22.96 | $13.05 | +1.18% |
| CNC | $29.41 | +2.08% | 14.4B | 7.13 | $4.12 | N/A |
| MOH | $174.44 | +0.93% | 9.4B | 8.59 | $20.28 | N/A |
| OSCR | $16.80 | +8.95% | 4.3B | -24.36 | -$0.69 | N/A |
Stock Comparison
GTS vs UNH Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, UNH has a market cap of 278.4B. Regarding current trading prices, GTS is priced at $35.99, while UNH trades at $307.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas UNH's P/E ratio is 13.32. In terms of profitability, GTS's ROE is +0.07%, compared to UNH's ROE of +0.22%. Regarding short-term risk, GTS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check UNH's competition here
GTS vs ANTM Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, GTS is priced at $35.99, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ANTM's P/E ratio is 18.99. In terms of profitability, GTS's ROE is +0.07%, compared to ANTM's ROE of +0.18%. Regarding short-term risk, GTS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ANTM's competition here
GTS vs CVS Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CVS has a market cap of 90.4B. Regarding current trading prices, GTS is priced at $35.99, while CVS trades at $71.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CVS's P/E ratio is 19.86. In terms of profitability, GTS's ROE is +0.07%, compared to CVS's ROE of +0.06%. Regarding short-term risk, GTS is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CVS's competition here
GTS vs CI Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CI has a market cap of 81.2B. Regarding current trading prices, GTS is priced at $35.99, while CI trades at $304.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CI's P/E ratio is 16.68. In terms of profitability, GTS's ROE is +0.07%, compared to CI's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CI's competition here
GTS vs ELV Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ELV has a market cap of 71.2B. Regarding current trading prices, GTS is priced at $35.99, while ELV trades at $316.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ELV's P/E ratio is 13.42. In terms of profitability, GTS's ROE is +0.07%, compared to ELV's ROE of +0.13%. Regarding short-term risk, GTS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ELV's competition here
GTS vs HUM Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, HUM has a market cap of 36B. Regarding current trading prices, GTS is priced at $35.99, while HUM trades at $299.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas HUM's P/E ratio is 22.96. In terms of profitability, GTS's ROE is +0.07%, compared to HUM's ROE of +0.09%. Regarding short-term risk, GTS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check HUM's competition here
GTS vs CNC Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CNC has a market cap of 14.4B. Regarding current trading prices, GTS is priced at $35.99, while CNC trades at $29.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CNC's P/E ratio is 7.13. In terms of profitability, GTS's ROE is +0.07%, compared to CNC's ROE of +0.08%. Regarding short-term risk, GTS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CNC's competition here
GTS vs MOH Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MOH has a market cap of 9.4B. Regarding current trading prices, GTS is priced at $35.99, while MOH trades at $174.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MOH's P/E ratio is 8.59. In terms of profitability, GTS's ROE is +0.07%, compared to MOH's ROE of +0.25%. Regarding short-term risk, GTS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MOH's competition here
GTS vs OSCR Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, OSCR has a market cap of 4.3B. Regarding current trading prices, GTS is priced at $35.99, while OSCR trades at $16.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas OSCR's P/E ratio is -24.36. In terms of profitability, GTS's ROE is +0.07%, compared to OSCR's ROE of -0.14%. Regarding short-term risk, GTS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check OSCR's competition here
GTS vs ALHC Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ALHC has a market cap of 3.1B. Regarding current trading prices, GTS is priced at $35.99, while ALHC trades at $15.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ALHC's P/E ratio is -58.63. In terms of profitability, GTS's ROE is +0.07%, compared to ALHC's ROE of -0.44%. Regarding short-term risk, GTS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ALHC's competition here
GTS vs CLOV Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CLOV has a market cap of 1.4B. Regarding current trading prices, GTS is priced at $35.99, while CLOV trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CLOV's P/E ratio is -34.12. In terms of profitability, GTS's ROE is +0.07%, compared to CLOV's ROE of -0.13%. Regarding short-term risk, GTS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CLOV's competition here
GTS vs BHG Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, GTS is priced at $35.99, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BHG's P/E ratio is -0.12. In terms of profitability, GTS's ROE is +0.07%, compared to BHG's ROE of -0.65%. Regarding short-term risk, GTS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BHG's competition here
GTS vs BMGL Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BMGL has a market cap of 37.2M. Regarding current trading prices, GTS is priced at $35.99, while BMGL trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BMGL's P/E ratio is 198.00. In terms of profitability, GTS's ROE is +0.07%, compared to BMGL's ROE of +0.32%. Regarding short-term risk, GTS is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BMGL's competition here
GTS vs MRAI Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MRAI has a market cap of 23.2M. Regarding current trading prices, GTS is priced at $35.99, while MRAI trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MRAI's P/E ratio is -0.46. In terms of profitability, GTS's ROE is +0.07%, compared to MRAI's ROE of +0.41%. Regarding short-term risk, GTS is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MRAI's competition here
GTS vs NIVF Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, NIVF has a market cap of 3.2M. Regarding current trading prices, GTS is priced at $35.99, while NIVF trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas NIVF's P/E ratio is -0.08. In terms of profitability, GTS's ROE is +0.07%, compared to NIVF's ROE of +0.03%. Regarding short-term risk, GTS is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check NIVF's competition here
GTS vs IVF Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, IVF has a market cap of 1M. Regarding current trading prices, GTS is priced at $35.99, while IVF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas IVF's P/E ratio is -0.01. In terms of profitability, GTS's ROE is +0.07%, compared to IVF's ROE of -5.98%. Regarding short-term risk, GTS is less volatile compared to IVF. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check IVF's competition here
GTS vs MGLN Comparison August 2025
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MGLN has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MGLN's P/E ratio is 8.49. In terms of profitability, GTS's ROE is +0.07%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, GTS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check MGLN's competition here